REFERENCES
M. S. Highley and E. A. DeBruijin. Erythrocytes and the transport of drugs and endogenous compounds. Pharm. Res. 13:186–195 (1996).
P. H. Hinderling. Red blood cells: a neglected compartment in pharmacokinetics and Pharmacodynamics. Pharmacol. Ref. 49: 279–295 (1997).
P. J. Wistrand. The use of carbonic anhydrase inhibitors in ophthalmology and medicine. Ann. NY Acad. Sci. 429:609–619 (1984).
C. T. Supuran, F. Brigant, and A. Scozzafava. Sulfonamidosulfonamides as inhibitors of carbonic anhydrase isozymes I, II, and IV. J. Enzyme Inhib. 12:175–190 (1997).
S. Lindskog and P. Nyman. Metal binding properties of human erythrocyte carbonic anhydrase. Biochim. Biophys. Acta 86:462–474 (1964).
S. Lindskog, L. E. Henderson, and K. K. Kannan. Carbonic Anhydrase: The Enzymes, 3ed edition, Academic Press, New York, 1971.
P. J. Wistrand and P. Baathe. Inhibition of carbonic anhydrase activity of whole erythrocytes. Acta Pharmacol. Toxicol. 26:145–168 (1968).
W. F. Bayne, F. T. Tao, G. Rogers, L. C. Chu, and F. Fheeuwes. Time course and disposition of methazolamide in human plasma and red blood cells. J. Pharm. Sci. 70:75–81 (1981).
T. H. Maren, J. R. Haywood, S. K. Chapman, and T. J. Zimmerman. The pharmacology of methazolamide in relation to the treatment of glaucoma. Invest. Ophthalmol. Vis. Sci. 16:730–742 (1977).
S. Pradhan, S. Praohan, A. T. Wu, L. L. Lesko, M.-L. Chen, and R. L. Williams. Bioavailability measurements of methazolamide in plasma, red blood cells and whole blood: Implications for bioequivalence studies. Int. J. Pharm. 138:207–213 (1996).
D. R. Taft, S. Nordt, G. R. Iyer, and M. H. Schwenk. Blood disposition and urinary excretion kinetics of methazolamide following oral administration to human subjects. Biopharm. Drug Dispos. 19:373–380 (1998).
G. R. Iyer, R. A. Bellantone, and D. R. Taft. In vitro characterization of the erythrocyte distribution of methazolamide: a model of erythrocyte transport and binding kinetics. J. Pharmacokinet. Biopharm. 27:45–66 (1999).
L. B. Holder and S. L. Hayes. Diffusion of sulfonamides in aqueous buffers and into red cells. Mol. Pharmacol. 1:266–279 (1965).
S. Shirato, F. Kagaya, Y. Suzuki, and S. Joukou. Stevens-Johnson syndrome induced by methazolamide treatment. Arch. Ophthalmol. 4:550–553 (1997).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
AbuTarif, M.A., Taft, D.R. Simulation of the Pharmacokinetic Profile of Methazolamide in Blood: Effect of Erythrocyte Carbonic Anhydrase Binding on Drug Disposition. Pharm Res 19, 551–555 (2002). https://doi.org/10.1023/A:1015120418178
Issue Date:
DOI: https://doi.org/10.1023/A:1015120418178